Surgery (St Vincent's) - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/169

Filters

2014 1
1
Reset filters

Settings
Statistics
Citations
Start date: 2010 × End date: 2019 × Author: Choong, Peter × Author: Slavin, John × Author: Achen, Marc ×

Search Results

Now showing 1 - 1 of 1
  • Item
    Thumbnail Image
    A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
    Lewin, J ; Khamly, KK ; Young, RJ ; Mitchell, C ; Hicks, RJ ; Toner, GC ; Ngan, SYK ; Chander, S ; Powell, GJ ; Herschtal, A ; Te Marvelde, L ; Desai, J ; Choong, PFM ; Stacker, SA ; Achen, MG ; Ferris, N ; Fox, S ; Slavin, J ; Thomas, DM (NATURE PUBLISHING GROUP, 2014-12-09)
    BACKGROUND: Preoperative radiotherapy (RT) is commonly used to treat localised soft-tissue sarcomas (STS). Hypoxia is an important determinant of radioresistance. Whether antiangiogenic therapy can 'normalise' tumour vasculature, thereby improving oxygenation, remains unknown. METHODS: Two cohorts were prospectively enrolled. Cohort A evaluated the implications of hypoxia in STS, using the hypoxic tracer (18)F-azomycin arabinoside (FAZA-PET). In cohort B, sunitinib was added to preoperative RT in a dose-finding phase 1b/2 design. RESULTS: In cohort A, 13 out of 23 tumours were hypoxic (FAZA-PET), correlating with metabolic activity (r(2)=0.85; P<0.001). Two-year progression-free (PFS) and overall (OS) survival were 61% (95% CI: 0.44-0.84) and 87% (95% CI: 0.74-1.00), respectively. Hypoxia was associated with radioresistance (P=0.012), higher local recurrence (Hazard ratio (HR): 10.2; P=0.02), PFS (HR: 8.4; P=0.02), and OS (HR: 41.4; P<0.04). In Cohort B, seven patients received sunitinib at dose level (DL): 0 (50 mg per day for 2 weeks before RT; 25 mg per day during RT) and two patients received DL: -1 (37.5 mg per day for entire period). Dose-limiting toxicities were observed in 4 out of 7 patients at DL 0 and 2 out of 2 patients at DL -1, resulting in premature study closure. Although there was no difference in PFS or OS, patients receiving sunitinib had higher local failure (HR: 8.1; P=0.004). CONCLUSION: In STS, hypoxia is associated with adverse outcomes. The combination of sunitinib with preoperative RT resulted in unacceptable toxicities, and higher local relapse rates.